Navigation Links
RNA aptamers targeted to plasminogen activator inhibitor
Date:6/19/2014

New Rochelle, NY, June 19, 2014Plasminogen activators are proteins involved in the breakdown of blood clots, and an elevated level of plasminogen activator inhibitor-1 (PAI-1) is associated with an increased risk for clotting and cardiovascular disease. No PAI-1 inhibitors are currently available for clinical use, but a novel therapeutic approach using a targeted RNA aptamer drug that has been shown to block PAI-1 activity and prevent PAI-1-associated vascular events is described in Nucleic Acid Therapeutics, a peer-reviewed journal from Nucleic Acid Therapeutics. The article is available free on the Nucleic Acid Therapeutics website.

Jared Damare, Stephanie Brandal, and Yolanda Fortenberry, Johns Hopkins University School of Medicine, Baltimore, MD, designed a library of small RNA molecules that target different regions of PAI-1. They then screened the library and enriched for the aptamers that were the most selective for binding to and inhibiting the function of PAI-1. The authors demonstrate the ability of these RNA aptamers to prevent PAI-1 from interacting with plasminogen activators in the article "Inhibition of PAI-1 Antiproteolytic Activity Against tPA by RNA Aptamers."

"Even beyond the admirable care and rigor of the work, the therapeutic significance lies in the authors addressing a vital concern: the identification of an aptamer that can specifically disrupt the target function of PAI-1 without inhibiting its other functions," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Single protein targeted as the root biological cause of several childhood psychiatric disorders
2. Tiny probes shine brightly to reveal the location of targeted tissues
3. 11th International Congress on Targeted Anticancer Therapies
4. Study opens new prospects for developing new targeted therapies for breast cancer
5. Protein targeted for cancer drug development is essential for normal heart function
6. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
7. Targeted culling of deer controls disease with little effect on hunting
8. Researchers use nanoscale patches to sensitize targeted cell receptors
9. Fruit pest targeted by genomic research
10. Targeted treatment can significantly reduce relapse in children with AML leukemia
11. Targeted synthesis of natural products with light
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
RNA aptamers targeted to plasminogen activator inhibitor
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: